Effect of metformin on the incidence of head and neck cancer in diabetics

Yung Chang Yen, Charlene Lin, Shih Wei Lin, Yong-Song Lin, Shih Feng Weng

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background The purpose of this study was to examine the effect of metformin on head and neck cancer in patients with diabetes. Methods We compared 66,600 patients, all with diabetes and all newly diagnosed with head and neck cancer in 2002. Half were being treated with metformin for diabetes (Met+) and half were not (Met-: controls). All were matched for comorbidities (obesity, coronary artery disease, hyperlipidemia, and hypertension), sex, and age. The risk of head and neck cancer at the end of 2011 was determined. Results The incidence of head and neck cancer was 34% lower in the Met+ cohort than in the Met- cohort (adjusted hazard ratio [HR] = 0.66; 95% confidence interval [CI] = 0.55-0.79). The risks for oropharyngeal cancer (adjusted HR = 0.66; 95% CI = 0.17-0.74) and nasopharyngeal carcinoma (NPC; adjusted HR = 0.50; 95% CI = 0.31-0.80) were significantly lower in the Met+ cohort than in the Met- cohort. Conclusion Metformin is associated with a lower risk of developing head and neck cancer in patients with diabetes.

Original languageEnglish
Pages (from-to)1268-1273
Number of pages6
JournalHead and Neck
Volume37
Issue number9
DOIs
Publication statusPublished - Sep 1 2015

Fingerprint

Metformin
Head and Neck Neoplasms
Incidence
Confidence Intervals
Oropharyngeal Neoplasms
Hyperlipidemias
Comorbidity
Coronary Artery Disease
Obesity
Hypertension

Keywords

  • diabetes
  • head and neck cancer
  • metformin
  • nasopharyngeal carcinoma
  • oral cancer

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Medicine(all)

Cite this

Yen, Y. C., Lin, C., Lin, S. W., Lin, Y-S., & Weng, S. F. (2015). Effect of metformin on the incidence of head and neck cancer in diabetics. Head and Neck, 37(9), 1268-1273. https://doi.org/10.1002/hed.23743

Effect of metformin on the incidence of head and neck cancer in diabetics. / Yen, Yung Chang; Lin, Charlene; Lin, Shih Wei; Lin, Yong-Song; Weng, Shih Feng.

In: Head and Neck, Vol. 37, No. 9, 01.09.2015, p. 1268-1273.

Research output: Contribution to journalArticle

Yen, YC, Lin, C, Lin, SW, Lin, Y-S & Weng, SF 2015, 'Effect of metformin on the incidence of head and neck cancer in diabetics', Head and Neck, vol. 37, no. 9, pp. 1268-1273. https://doi.org/10.1002/hed.23743
Yen, Yung Chang ; Lin, Charlene ; Lin, Shih Wei ; Lin, Yong-Song ; Weng, Shih Feng. / Effect of metformin on the incidence of head and neck cancer in diabetics. In: Head and Neck. 2015 ; Vol. 37, No. 9. pp. 1268-1273.
@article{37e7e46fb37e462690480f6909b8937c,
title = "Effect of metformin on the incidence of head and neck cancer in diabetics",
abstract = "Background The purpose of this study was to examine the effect of metformin on head and neck cancer in patients with diabetes. Methods We compared 66,600 patients, all with diabetes and all newly diagnosed with head and neck cancer in 2002. Half were being treated with metformin for diabetes (Met+) and half were not (Met-: controls). All were matched for comorbidities (obesity, coronary artery disease, hyperlipidemia, and hypertension), sex, and age. The risk of head and neck cancer at the end of 2011 was determined. Results The incidence of head and neck cancer was 34{\%} lower in the Met+ cohort than in the Met- cohort (adjusted hazard ratio [HR] = 0.66; 95{\%} confidence interval [CI] = 0.55-0.79). The risks for oropharyngeal cancer (adjusted HR = 0.66; 95{\%} CI = 0.17-0.74) and nasopharyngeal carcinoma (NPC; adjusted HR = 0.50; 95{\%} CI = 0.31-0.80) were significantly lower in the Met+ cohort than in the Met- cohort. Conclusion Metformin is associated with a lower risk of developing head and neck cancer in patients with diabetes.",
keywords = "diabetes, head and neck cancer, metformin, nasopharyngeal carcinoma, oral cancer",
author = "Yen, {Yung Chang} and Charlene Lin and Lin, {Shih Wei} and Yong-Song Lin and Weng, {Shih Feng}",
year = "2015",
month = "9",
day = "1",
doi = "10.1002/hed.23743",
language = "English",
volume = "37",
pages = "1268--1273",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Effect of metformin on the incidence of head and neck cancer in diabetics

AU - Yen, Yung Chang

AU - Lin, Charlene

AU - Lin, Shih Wei

AU - Lin, Yong-Song

AU - Weng, Shih Feng

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Background The purpose of this study was to examine the effect of metformin on head and neck cancer in patients with diabetes. Methods We compared 66,600 patients, all with diabetes and all newly diagnosed with head and neck cancer in 2002. Half were being treated with metformin for diabetes (Met+) and half were not (Met-: controls). All were matched for comorbidities (obesity, coronary artery disease, hyperlipidemia, and hypertension), sex, and age. The risk of head and neck cancer at the end of 2011 was determined. Results The incidence of head and neck cancer was 34% lower in the Met+ cohort than in the Met- cohort (adjusted hazard ratio [HR] = 0.66; 95% confidence interval [CI] = 0.55-0.79). The risks for oropharyngeal cancer (adjusted HR = 0.66; 95% CI = 0.17-0.74) and nasopharyngeal carcinoma (NPC; adjusted HR = 0.50; 95% CI = 0.31-0.80) were significantly lower in the Met+ cohort than in the Met- cohort. Conclusion Metformin is associated with a lower risk of developing head and neck cancer in patients with diabetes.

AB - Background The purpose of this study was to examine the effect of metformin on head and neck cancer in patients with diabetes. Methods We compared 66,600 patients, all with diabetes and all newly diagnosed with head and neck cancer in 2002. Half were being treated with metformin for diabetes (Met+) and half were not (Met-: controls). All were matched for comorbidities (obesity, coronary artery disease, hyperlipidemia, and hypertension), sex, and age. The risk of head and neck cancer at the end of 2011 was determined. Results The incidence of head and neck cancer was 34% lower in the Met+ cohort than in the Met- cohort (adjusted hazard ratio [HR] = 0.66; 95% confidence interval [CI] = 0.55-0.79). The risks for oropharyngeal cancer (adjusted HR = 0.66; 95% CI = 0.17-0.74) and nasopharyngeal carcinoma (NPC; adjusted HR = 0.50; 95% CI = 0.31-0.80) were significantly lower in the Met+ cohort than in the Met- cohort. Conclusion Metformin is associated with a lower risk of developing head and neck cancer in patients with diabetes.

KW - diabetes

KW - head and neck cancer

KW - metformin

KW - nasopharyngeal carcinoma

KW - oral cancer

UR - http://www.scopus.com/inward/record.url?scp=84938994745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938994745&partnerID=8YFLogxK

U2 - 10.1002/hed.23743

DO - 10.1002/hed.23743

M3 - Article

C2 - 24801563

AN - SCOPUS:84938994745

VL - 37

SP - 1268

EP - 1273

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

IS - 9

ER -